Investors

News Release

Printer Friendly Version View printer-friendly version
<< Back
Cell Therapeutics Adjourns Special Meeting of Shareholders Until May 14, 2010

SEATTLE, April 9, 2010 /PRNewswire via COMTEX/ --Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that the Company has adjourned today's Special Meeting of Shareholders (the "Special Meeting") to 10:00 am Pacific Daylight Time, Friday, May 14, 2010. The Company's proxy materials previously filed with the Securities and Exchange Commission (the "SEC") on February 23, 2010 and the proposals being submitted to a vote of the shareholders at the Special Meeting as described in such proxy materials remain unchanged. The Company encourages those shareholders that held shares as of the February 19, 2010, the record date of the Special Meeting, to vote their shares on the proposals.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the Company might not be able to continue to raise additional capital as needed to fund its operations, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon




    Media Contact:                        Investors Contact:
    Dan Eramian                           Ed Bell
    T: 206.272.4343                       T: 206.272.4345
    C: 206.854.1200                       Lindsey Jesch Logan
    F: 206.272.4434                       T: 206.272.4347
    E: deramian@ctiseattle.com            F: 206.272.4434
    www.celltherapeutics.com/press_room   E: invest@ctiseattle.com
                                          www.celltherapeutics.com/investors





SOURCE Cell Therapeutics, Inc.